Modelling A.I. in Economics

NASDAQ: IMMP Stock Forecast


Immutep Limited (ASX: IMM, NASDAQ: IMMP) is a biotechnology company headquartered in Sydney, Australia, with a focus on developing novel immunotherapy treatments. Here is a profile of Immutep ADS:

1. Immunotherapy Focus: Immutep is primarily focused on developing immunotherapy treatments that harness the power of the immune system to fight cancer and autoimmune diseases. The company's approach involves targeting a protein called LAG-3 (Lymphocyte-Activation Gene 3) to modulate immune responses.

2. Lead Product Candidate: Immutep's lead product candidate is called eftilagimod alpha (efti), previously known as IMP321. It is a soluble LAG-3 protein that acts as a potential immunomodulator, enhancing immune responses against cancer cells. Efti is being evaluated in various clinical trials for different types of cancer.

3. Clinical Pipeline: In addition to efti, Immutep has other product candidates in its clinical pipeline. This includes IMP761, which targets autoimmune diseases, and IMP701, an antibody that blocks LAG-3 signaling.

4. Collaborations and Partnerships: Immutep collaborates with various academic institutions, pharmaceutical companies, and research organizations to advance its immunotherapy programs. These collaborations help in conducting clinical trials, exploring combination therapies, and expanding the potential applications of LAG-3 in treating diseases.

5. Global Presence: While Immutep is headquartered in Australia, it has a global presence and operates in multiple countries. It conducts clinical trials and research activities in collaboration with partners across the United States, Europe, and Asia.

6. Stock Exchange Listings: Immutep's ordinary shares are listed on the Australian Securities Exchange (ASX) under the ticker symbol "IMM." The company's American Depositary Shares (ADS) are listed on the NASDAQ stock exchange under the ticker symbol "IMMP."

Immutep's ADS represents an ownership interest in Immutep's ordinary shares traded on the Australian Securities Exchange (ASX). Each ADS typically represents a certain number of underlying ordinary shares, allowing investors to trade Immutep's shares on the NASDAQ.

Immutep's stock performance is subject to market fluctuations and can be influenced by various factors, including clinical trial results, regulatory approvals, financial performance, investor sentiment, and overall market conditions.

Immutep Limited  is assigned short-term Ba1 & long-term Ba1 estimated rating. Immutep Limited prediction model is evaluated with Statistical Inference (ML) and Stepwise Regression1,2,3,4 and it is concluded that the NASDAQ: IMMP stock is predictable in the short/long term. According to price forecasts for (n+3 month) period, the dominant strategy among neural network is: Strong Buy


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.